Phosphodiesterase-4 inhibitors: a review of current developments (2010 – 2012)

Bibliography

• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signalling. Ann Rev Biochem 2007;76:481-511
   PubMed Web of Science ®Google Scholar
• Bingham J, Sudarsanam S, Srinivasan S. Profiling human phosphodiesterase genes and splice isoforms. Biochem Biophys Res Commun 2006;350:25-32
   PubMedGoogle Scholar
• Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 2010;35:91-100
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-19
   PubMed Web of Science ®Google Scholar
• Press NJ, Banner KH. PDE4 inhibitors - a review of the current field. Prog Med Chem 2009;47:37-74
   PubMedGoogle Scholar
• O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004;25:158-63.
   PubMed Web of Science ®Google Scholar
• Robichaud A, Stamatiou PB, Jin S-L, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002;110:1045-52
   PubMed Web of Science ®Google Scholar
• Li YF, Cheng YF, Huang Y, et al. Phosphodiesterase-4D knockout and RNAi-mediated knockdown enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 2011;31:172-83
   PubMed Web of Science ®Google Scholar
• Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009;15:1688-98
   PubMed Web of Science ®Google Scholar
• Wang H, Peng MS, Chen Y, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J 2007;408:193-201
   PubMed Web of Science ®Google Scholar
• Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFα responses. Proc Natl Acad Sci USA 2002;99:7628-33
   PubMed Web of Science ®Google Scholar
• Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999;128:1393-8
   PubMed Web of Science ®Google Scholar
• Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005;123:25-35
   PubMed Web of Science ®Google Scholar
• Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anaesthesia, a behavioural correlate of emesis. J Clin Invest 2002;110:1045-52
   PubMed Web of Science ®Google Scholar
• Mori F, Pérez-Torres S, De Caro R, et al. The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 2010;40:36-42
   PubMedGoogle Scholar
• Summary of the European public assessment report (EPAR) for Daxas. Avaialble from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001179/human_med_001363.jsp&mid=WC0b01ac058001d124 [Last accessed 15 January 2013]
   Google Scholar
• FDA News release. 2011. Avaialble from http://www.fda.gov/NewsEvents/newsroom/PressAnnouncements/ucm244989.htm [Last accessed 15 January 2013]
   Google Scholar
• GOLD. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org [Last accessed 15 January 2013]
   Google Scholar
• Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor Roflumilast – the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18
   PubMed Web of Science ®Google Scholar
• Clinical trials for Roflumilast. Avaialble from http://www.clinicaltrials.gov/ct2/results?term=roflumilast [Last accessed 15 January 2013]
   Google Scholar
• Pagès L, Gavaldà A, Lehner MD. PDE4 inhibitors: a review of current developments (2005 - 2009). Expert Opin Ther Pat 2009;19:1501-19
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55
   PubMed Web of Science ®Google Scholar
• Celgene product pipeline. Avaialble from http://www.celgene.com/pdfs/product_pipeline.pdf [Last accessed 15 January 2013]
   Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of Apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380:738-46
   PubMed Web of Science ®Google Scholar
• Positive phase IIb topline clinical data for celgene oral compound apremilast (CC-10004) reported for patients with moderate-to-severe. Avaialble from http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1365878&highlight=apremilast [Last accessed 15 January 2013]
   Google Scholar
• Phase II study evaluating apremilast as an oral treatment for patients with Ankylosing Spondylitis Presented at ACR. Avaialble from http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1627508&highlight=apremilast [Last accessed 15 January 2013]
   Google Scholar
• Oral apremilast achieves statistical significance for the primary endpoint of ACR20 in the first phase III study (PALACE-1) in patients with psoriatic arthritis. Avaialble from http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle_print&ID=1758233&highlight= [Last accessed 15 January 2013]
   Google Scholar
• Apremilast ESTEEM program meets primary and major secondary endpoint in pivotal phase III psoriasis trials. Avaialble from http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1771804&highlight= [Last accessed 15 January 2013]
   Google Scholar
• Clinical trials for Apremilast. Avaialble from http://www.clinicaltrials.gov/ct2/results?term=apremilast&pg=1 [Last accessed 15 January 2013]
   Google Scholar
• Lötvall J, Lundbäck B. Phosphodiesterase inhibitors in obstructive lung disease. In: Lötvall J, editor. Advances in combination therapy for asthma and COPD. John Wiley and Sons, Hoboken, NJ; 2012
   Google Scholar
• Glenmark initiates phase IIb human trials globally for its novel Molecule Revamilast. Avaialble from http://www.glenmarkpharma.com/GLN_NWS/PDF/Revamilast_PhII_initiated.pdf [Last accessed 15 January 2013]
   Google Scholar
• Clinical trials for Revamilast. Avaialble from http://clinicaltrials.gov/ct2/results?term=Revamilast [Last accessed 15 January 2013]
   Google Scholar
• A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis (TERRA). Avaialble from http://clinicaltrials.gov/ct2/show/NCT01430507?term=Revamilast&rank=1 [Last accessed 15 January 2013]
   Google Scholar
• A clinical trial to study the effects of revamilast in patients with chronic persistent asthma. Avaialble from http://clinicaltrials.gov/ct2/show/NCT01436890?term=Revamilast&rank=2 [Last accessed 15 January 2013]
   Google Scholar
• Santen Pharmaceutical Co, Ltd. Annual Report 2009. Avaialble from http://www.santen.com/ir/events/mtg2009_3q.pdf [Last accessed 15 January 2013]
   Google Scholar
• Shakur Y, Hensley J, Kambayashi J. Tetomilast (OPC-6535): Inhibition of human T-cell proliferation and cytokine release [abstract MON-G-135]. 14th United Eur Gastroenterol Week (UEGW); 21 – 25 October 2006; Berlin
   Google Scholar
• Ichikawa H, Okamoto S, Kamada N, et al. Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. Inflamm Bowel Dis 2008;11:1483-90
   Google Scholar
• Hasegawa T, Sakurai K, Kambayashi Y, et al. Effects of OPC-6535 on lipopolysaccharide-induced acute liver injury in the rat: involvement of superoxide and tumor necrosis factor-alpha from hepatic macrophages. Surgery 2003;134:818-26
   PubMedGoogle Scholar
• Nagamoto H, Maeda T, Haruta JP, et al. OPC-6535, a novel oral thiazole compound, supresses colonic damage in a rat model of T-induced colitis. Gastroenterology 2004;126(Suppl2):M1044
   PubMedGoogle Scholar
• Bloomfield GL, Ridings PC, Blocher CR, et al. OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury. J Surg Res 1997;72:70-7
   PubMed Web of Science ®Google Scholar
• Onogawa T, Nagamoto H, Maeda T, et al. The protective effect of an inhibitor of leukocyte activation (OPC-6535) on myocardial reperfusion injury in a pig model. J Mol Cell Cardiol 1998;30:A37
   Google Scholar
• Bickston SJ, Snider KR, Kappus MR. Tetomilast: new promise for phosphodiesterase-4 inhibitors? Expert Opin Investig Drugs 2012;21:1845-9
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Shoaf S, Zhang P, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of Tetomilast in stable COPD subjects [abstract No. P3838]. European Respiratory Society (ERS) 2006 Congress; Munich, Germany; 2006
   Google Scholar
• Wise RA, Littner MR, Zhang P, et al. Clinical evaluation of a new inhibitor of neutrophilic inflammation, Tetomilast (OPC-6535) in chronic obstructive pulmonary disease [abstract No. P3052]. European Respiratory Society (ERS) 2006 Congress; Munich, Germany; 2006
   Google Scholar
• Clinical trials for Tetomilast. Available from: http://www.clinicaltrials.gov/ct2/results?term=tetomilast [Last accessed 15 January 2013]
   Google Scholar
• Leaker BR, Singh D, Barnes PJ, et al. The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen-induced responses in mild asthma [Poster Board: J18, Publication Page: A5613]. American Thoracic Society International Conference; 14 – 19 May2010; New Orleans
   Google Scholar
• Roche pharmaceuticals pipeline. Available from: http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm [Last accessed 15 January 2013]
   Google Scholar
• Kuss H, Egerland U, Hoefgen N, et al. The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE4) inhibitor for the treatment of allergic asthma and COPD. Eur Resp J 2003;22(Suppl 45):P742
   Google Scholar
• Piggott C. Ronomilast (ELB353, PDE4 inhibitor), Euro-Biotech Forum Paris, 2010
   Google Scholar
• Biotie Product and development. Available from: http://www.biotie.com/en/product_and_development/inflammation/ronomilast [Last accessed 15 January 2013]
   Google Scholar
• Bloomberg press release. Available from: http://www.bloomberg.com/news/2013-01-21/biotie-considers-developing-alzheimer-s-drug-on-its-own.html?cmpid=yhoo [Last accessed 31 January 2013]
   Google Scholar
• Tralau-Stewart CJ, Williamson RA, Nials AT, et al. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther 2011;337:145-54
   PubMed Web of Science ®Google Scholar
• Singh D, Petavy F, Macdonald AJ, et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010;11:26
   PubMed Web of Science ®Google Scholar
• GSK product pipeline. Available from: http://www.gsk.com/investors/product-pipeline.html [Last accessed 17 January 2013]
   Google Scholar
• A single dose of RPL554 is safe and effective in patients with asthma. 2009. Available from: http://www.veronapharma.com/joomla/news/project-news/2009/163-a-single-dose-of-rpl554-is-safe-and-effective-in-patients-with-asthma [Last accessed 15 January 2013]
   Google Scholar
• Verona Pharma announces positive results for RPL554 in mild asthma at higher doses. 2011. Available from: http://www.veronapharma.com/joomla/images/Documents/News/2011-02-22_NRa.pdf [Last accessed 15 January 2013]
   Google Scholar
• Bronchodilation in asthmatics maintained with daily dosing of RPL554. 2011. Available from: http://www.veronapharma.com/joomla/images/Documents/News/2011-08-17_NR.pdf [Last accessed 15 January 2013]
   Google Scholar
• Verona Pharma reports bronchodilator data with RPL554 in COPD patients at the 2012 European Respiratory Society. 2012. Available from: http://www.veronapharma.com/joomla/images/Documents/News/2012-09-04_NR.pdf [Last accessed 15 January 2013]
   Google Scholar
• Zane LT, Toledo-Bahena M, Hughes MH, et al. Safety and Efficacy of AN2728 Ointment in a Phase 2b Dose-Ranging, Bilateral Study of Mild-to-Moderate Plaque Psoriasis. 71st Society of Investigative Dermatology (SID) meeting; 4 – 7 May 2011; Phoenix, Arizona
   Google Scholar
• Toledo-Bahena M, Zane LT. Safety and efficacy of AN2728 ointment in a 12-week, randomized, double-blind, vehicle- controlled, bilateral trial for the treatment of psoriasis. 41st European Society for Dermatological Research (ESDR); 7 – 10 Sept 2011; Barcelona, Spain
   Google Scholar
• Zane LT, Gogoleva T, Heerinckx FA, et al. Safety and efficacy of AN2728 and AN2898 ointments in a phase 2a bilateral study of mild-to-moderate atopic dermatitis. 72nd Society of Investigative Dermatology (SID)Raleigh; 9 – 12 May 2012; North Carolina
   Google Scholar
• Anacor pipeline AN2728. Available from: http://www.anacor.com/an2728.php [Last accessed 15 January 2013]
   Google Scholar
• Sanders V, Rock F, Kimura R, et al. AN2898, a novel oxaborole compound with anti-inflammatory activity: mechanism of action and in vitro cytokine inhibition. International Investigative Dermatology Conference, 14 – 18 May 2008; Kyoto, Japan
   Google Scholar
• Maples K, Bu W, Liu L, et al. AN2898, a novel oxaborole compound with anti-inflammatory activity: results of in vivo efficacy and preclinical safety studies. International Investigative Dermatology Conference; 14 – 18 May 2008; Kyoto, Japan
   Google Scholar
• Eisai 2012 Major R&D pipeline. Available from: www.eisai.com/pdf/eir/erepo/epipeline.pdf [Last accessed 15 January 2013]
   Google Scholar
• Card GL, England BP, Suzuki Y, et al. structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004;12:2233-47
   PubMed Web of Science ®Google Scholar
• Auspex Pharmaceuticals Inc. Pyrrolidinone inhibitors of PDE-4. US20100159034; 2010
   Google Scholar
• Celgene Corporation. Isotopologues of isoindole derivatives. WO2012097116; 2012
   Google Scholar
• Concert Pharmaceuticals Inc. Deuterated isoindoline-1,3-dione derivatives as PDE4 and THF-alpha inhibitors. WO2010147922; 2010
   Google Scholar
• Concert Pharmaceuticals Inc. KR2012071261; 2012
   Google Scholar
• Celgene Corporation. Phenethylsulfone isoindoline derivatives and their use. US20120178708; 2012
   Google Scholar
• Tianjin Hemay Biotech Co. Ltd. Thiophene derivatives. WO2010130224; 2010
   Google Scholar
• Nektar Therapeutics. Oligomer-containing apremilast moiety compounds. WO2012083153; 2012
   Google Scholar
• Chiesi Farmaceutici SPA. Ester derivatives as phosphodiesterase inhibitors. WO2009077068; 2009; Chiesi Farmaceutici SPA. EP2070913; 2009
   Google Scholar
• Chiesi Farmaceutici SPA. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class. US20090258905; 2009
   Google Scholar
• Chiesi Farmaceutici SPA. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors. WO2010089107; 2010; Chiesi Farmaceutici SPA. EP2216327; 2010
   Google Scholar
• Chiesi Farmaceutici SPA. Pharmaceutical formulation comprising a phosphodiesterase inhibitor. WO2012016845; 2012
   Google Scholar
• Chiesi Farmaceutici SPA. Dry powder formulation comprising a phosphodiesterase inhibitor. WO2012016889; 2012
   Google Scholar
• Chiesi Farmaceutici SPA. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors. WO2012168226; 2012
   Google Scholar
• Leo Pharma AS. Biaryl phosphodiesterase inhibitors. WO2011134468; 2011
   Google Scholar
• LeoPharma AS. Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors. WO2011160632; 2011
   Google Scholar
• Kalypsys Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4. WO2011093924; 2011; Kalypsys Inc. US20100081646; 2010
   Google Scholar
• Via Pharmaceuticals Inc. 5-Substituted-1,4-benzodiazepines as phosphodiesterase inhibitors. WO2009037302; 2009
   Google Scholar
• Nycomed GMBH. Novel pyrazolone-derivatives and their use as PD4 inhibitors. WO2010055083; 2010
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Ointment with excellent formulation stability. WO2012133492; 2012
   Google Scholar
• Helicon Therapeutics Inc. Therapeutic piperazines. WO2012040258; 2012; Helicon Therapeutics Inc. US20110065691; 2011
   Google Scholar
• Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors. WO2010003084; 2010
   Google Scholar
• H. L. Hall & Sons Ltd. Use of pharmaceutical compositions containing mesembrenone. WO2010106494; 2010
   Google Scholar
• H. L. Hall & Sons Ltd. Sceletium extract and uses thereof. WO2010106495; 2010
   Google Scholar
• Taipei Medical University. Pharmaceutical composition containing flavinoids. US20090036518; 2009
   Google Scholar
• The United States of America, as represented by the Secretary, Department of Health and Human Services. Phosphodiesterase inhibitors. WO2009089027; 2009
   Google Scholar
• Korea Research Institute of Chemical Technology, S Korea. KR2009058752; 2009
   Google Scholar
• People's Republic of China. CN102716110; 2012
   Google Scholar
• 4 Aza IP NV. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment. WO2009003669; 2009
   Google Scholar
• Council of Scientific & Industrial Research. Triazine-aryl-bis-indoles and process for preparation thereof. WO2011092547; 2011
   Google Scholar
• Leo Pharma AS. Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases. WO2010069322; 2010
   Google Scholar
• Kyorin Pharmaceutical Co. Ltd. Heterocyclic biaryl derivative, and PDE4 inhibitor comprising same as active ingredient. WO2010035745; 2010
   Google Scholar
• Matrix Laboratories Ltd. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation. WO2009115874; 2009
   Google Scholar
• Matrix Laboratories Ltd. Novel PDE inhibitors, pharmaceutical compositions containing them and processes for their preparation. WO2009147476; 2009
   Google Scholar
• Nuada Inc. Method for treatment of bronchial asthma. US20120202868; 2012
   Google Scholar
• Orchid Research Laboratories Ltd. Heterocyclic compounds as phosphodiesterase inhibitors. WO2010084402; 2010; Orchid Research Laboratories Ltd. US2011269753; 2011
   Google Scholar
• High Point Pharmaceuticals LLC. Tricyclic compounds as modulators of TNF-a synthesis and as PDE4 inhibitors. WO2009094528; 2009
   Google Scholar
• Almirall SA. (3-Oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors. WO2010069504; 2010; Almirall SA. EP2196465; 2010
   Google Scholar
• Almirall SA. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors. EP2394998; 2011
   Google Scholar
• Almirall SA. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives. WO2010097172; 2010; EP2226323; 2010
   Google Scholar
• Almirall SA. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors. EP2380890; 2011
   Google Scholar
• Astellas Pharma Inc. Imidazo[1,2-a]pyridine derivative. WO2011136192; 2011
   Google Scholar
• Anacor Pharmaceuticals Inc. Boron-containing small molecules. WO2009111676; 2009
   Google Scholar
• Anacor Pharmaceuticals Inc. Boron-containing small molecules. WO2010027975; 2010
   Google Scholar
• Anacor Pharmaceuticals Inc. Boron-containing small molecules. WO2010028005; 2010
   Google Scholar
• AstraZeneca AB. Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states. WO2009144494; 2009
   Google Scholar
• AstraZeneca AB. Combination comprising 6-fluoro-N-((1S,4S)-4-(6-fluoro-2,4-dioxo-1-(4â-(piperazin-1-yl-methyl)biphenyl-3-yl)-1,2-dihydropyrido[2,3-d]pyrimidin-3(4H)-yl)cyclohexyl)imidazo[1,2-a]pyridine-2-carboxamide or a salt. WO2010004319; 2010
   Google Scholar
• DeCode Genetics EHF. Substituted benzoazole PDE4 inhibitors for treating pulmonary and cardiovascular disorders. US20090130076; 2009
   Google Scholar
• DeCode Genetics EHF. 4- (or 5-) substituted catechol derivatives. US20090131530; 2009
   Google Scholar
• DeCode Genetics EHF. Biaryl PDE4 inhibitors for treating inflammation. WO2009067600; 2009
   Google Scholar
• DeCode Genetics EHF. Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders. WO2009067621; 2009
   Google Scholar
• DeCode Genetics EHF. Substituted aza-bridged bicyclics for cardiovascular and CNS disease. WO2010059836; 2010
   Google Scholar
• DeCode Genetics EHF. PDE4 inhibitors selective for the long form of PDE4 for treating inflammation and avoiding side effects. WO2010059838; 2010
   Google Scholar
• Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotech 2010;28:63-72
   PubMed Web of Science ®Google Scholar
• People's Republic of China. CN102603676; 2012
   Google Scholar
• Orchid Research Laboratories Ltd. Novel heterocycles. WO2009095773; 2009
   Google Scholar
• Gilead Sciences Inc. Bi-functional quinoline analogs. US20110275622; 2011
   Google Scholar
• Gilead Sciences Inc. Bi-functional pyrazolopyridine compounds. US20110275623; 2011
   Google Scholar
• Glaxo Group Ltd. Dual pharmacophores-PDE4-muscarinic antagonistics. WO2009100166; 2009
   Google Scholar
• Glaxo Group Ltd. Dual pharmacophores-PDE4-muscarinic antagonistics. WO2009100167; 2009
   Google Scholar
• Glaxo Group Ltd. Dual pharmacophores-PDE4-muscarinic antagonistics. US20090197871; 2009
   Google Scholar
• Glaxo Group Ltd. Dual pharmacophores-PDE4-muscarinic antagonistics. WO2009100169; 2009
   Google Scholar
• Glaxo Group Ltd. Dual pharmacophores-PDE4-muscarinic antagonistics. WO2009100170; 2009
   Google Scholar
• Human Biomolecular Research Institute. Modulators of central nervous system neurotransmitters. WO2006025920; 2006
   Google Scholar
• Cashman JR, Voelker T, Zhang H-T, et al. Dual inhibitors of phosphodiesterase-4 and serotonin re-uptake. J Med Chem 2009;52:1530-9
   PubMedGoogle Scholar
• Kyorin Seiyaku KK. JP2010013354; 2010
   Google Scholar
• Nycomed GMBH. 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[4,3-c]isoquinoline derivatives. WO2011073231; 2011
   Google Scholar
• Biolipox AB. Pyrimidinone derivaties for use as medicaments. WO2010029299; 2010
   Google Scholar
• Biolipox AB. Pyrimidinones for use as medicaments. WO2011114103; 2011
   Google Scholar
• Biolipox AB. Isochromenones useful in the treatment of inflammation. WO2010076564; 2010
   Google Scholar
• Ranbaxy Laboratorios Ltd. Phosphodiesterase inhibitors. WO2010046791; 2010
   Google Scholar
• Trustees Boston College. Inhibitors of cyclic AMP phosphodiesterases. US20100227853; 2010
   Google Scholar
• Gaeta FCA, Ledeboer A, Gross MI, Johnson KW. Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity. WO2010144416; 2010
   Google Scholar
• Basilea Pharmaceutica AG. Macrolides for treating diseases mediated through PDE inhibition. WO2009098320; 2009
   Google Scholar
• Basilea Pharmaceutica AG. New macrolides and their use. WO2009106419; 2009
   Google Scholar
• Basilea Pharmaceutica AG. New macrolides and their use. WO2011018510; 2011
   Google Scholar
• Joshi T, Hill SM, Tannheimer S, et al. GS-5759, a novel Bi-functional Phosphodiesterase 4 Inhibitor and Long-Acting Beta2-Adrenoreceptor Agonist, augments GRE-dependent transcription in Human airway epithelial cells. American Thoracic Society International Conference; 18 – 23 May 2012. p. E22
   Google Scholar
• Gentzler TT, Cui ZH, Hartsough KC, et al. GS-5759, a novel Bi-functional Phosphodiesterase 4 Inhibitor and Long-Acting Beta2-Adrenoreceptor Agonist Is Efficacious in Rodent Models of Pulmonary Inflammation and Does not cause emesis in Ferrets. American Thoracic Society International Conference; 18 – 23 May 2012. p. E25
   Google Scholar
• McDonald J, Doyle-Eisele M, Rudolph K, et al. GS-5759, a novel Bi-functional Phosphodiesterase 4 Inhibitor and Long-Acting Beta2-Adrenoreceptor Agonist: Evaluation of its Bronchodilator and Anti-inflammatory Pharmacology in Non-human Primates. American Thoracic Society International Conference; 18 – 23 May 2012. p. E27
   Google Scholar
• Cui Z, Gentzler TT, Wright CD, et al. GS-5759, a novel Bi-functional phosphodiesterase 4 inhibitor and long-acting beta2-adrenoreceptor agonist, in vivo characterization of the bronchodilator pharmacology and safety in guinea pigs. American Thoracic Society International Conference; 18 – 23 May 2012. p. J4
   Google Scholar
• Xu RX, Hassell AM, Vanderwall D, et al. Atomic Structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science 2000;288:1822-5
   PubMed Web of Science ®Google Scholar
• Huai Q, Colicelli J, Ke H. The crystal structure of AMP-Bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 2003;42:13220-6
   PubMed Web of Science ®Google Scholar
• Wang H, Robinson H, Ke H. The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. J Mol Biol 2007;371:302-7
   PubMed Web of Science ®Google Scholar
• Huai Q, Sun Y, Wang H, et al. enantiomer discrimination illustrated by the high resolution crystal structure of type 4 phosphodiesterase. J Med Chem 2006;49:1867-73
   PubMedGoogle Scholar
• Hamblin JN, Angell TDR, Ballantine SP, et al. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Lett 2008;18:4237-41
   PubMed Web of Science ®Google Scholar
• Lunniss CJ, Cooper AWJ, Eldred CD, et al. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for oral administration. Bioorg Med Chem Lett 2009;19:1380-5
   PubMedGoogle Scholar
• Woodrow MD, Ballantine SP, Barker MD. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. Bioorg Med Chem Lett 2009;19:5261-5
   PubMedGoogle Scholar
• Govek SP, Oshiro G, Anzola JV, et al. Water-soluble PDE4 inhibitors for the treatment of dry eye. Bioorg Med Chem Lett 2010;20:2928-32
   PubMedGoogle Scholar
• Nankervis JL, Feil SC, Hancock NC, et al. Thiophene inhibitors of PDE4: Crystal structures show a second binding mode at the catalytic domain of PDE4D2. Bioorg Med Chem Lett 2011;21:7089-93
   PubMedGoogle Scholar